# SkinBioTherapeutics Receives provisional ethics approval for human study

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-receives-provisional-ethics-approval-human-study/412754907
- Published: 2018-07-18T07:17:11+01:00
- Author: Giles Arbor

**SkinBioTherapeutics plc** (LON:SBTX), a life sciences company focused on skin 
health, announced today that it has received provisional ethics approval for its
[human study](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)
scheduled to start later this year.

Full approval will be granted on completion of procedural amendments to the study
paperwork which are underway.

The human study, scheduled for September 2018, will be conducted on 120 female volunteers
with self-assessed ‘dry skin’ over a six week period. The study is designed to test
whether the positive impact of the SkinBiotix® technology on the skin’s barrier 
function, which has been demonstrated in laboratory studies, is replicated with 
human volunteers. Measurements will be taken to assess skin dryness, skin hydration
and the skin barrier function.

>  **Dr Catherine O’Neill, CEO of SkinBioTherapeutics Plc, commented:** “Ethics 
> approval is a prerequisite for human clinical trials and therefore required before
> our human study can commence. The procedural amendments we need to make to the
> paperwork are straightforward and consequently we remain on track to commence 
> the human study in September.”

Share on: